(Q44111168)

29 November 2017

title

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies (English)

1 reference

29 November 2017

1 reference

1

1 reference

29 November 2017

Guillermo Martín

3

0 references

Rafael Andreu

object named as

Rafael Andreu

9

1 reference

ORCID Public Data File 2021

author name string

Ana Regadera

2

1 reference

29 November 2017

José Cervera

4

1 reference

29 November 2017

Guillermo Sanz

5

1 reference

29 November 2017

Jesús Martínez

6

1 reference

29 November 2017

Isidro Jarque

7

1 reference

29 November 2017

Inmaculada García

8

1 reference

29 November 2017

Federico Moscardó

10

1 reference

29 November 2017

Carmen Jiménez

11

1 reference

29 November 2017

Susana Mollá

12

1 reference

29 November 2017

Luis Benlloch

13

1 reference

29 November 2017

Miguel Sanz

14

1 reference

29 November 2017

language of work or name

1 reference

1 August 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

26

1 reference

29 November 2017

issue

8

1 reference

29 November 2017

page(s)

725-730

1 reference

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Treatment of therapy-related leukemia and myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

Neurotoxicity of purine analogs: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900003-6

7 January 2021

10.1016/S0145-2126(02)00003-6

Identifiers

DOI

1 reference

29 November 2017

1 reference